Article citationsMore>>

Cheng, Y., Fan, Y., Zhao, Y., Huang, D., Li, X., Zhang, P., et al. (2024) Tislelizumab Plus Platinum and Etoposide versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. Journal of Thoracic Oncology, 19, 1073-1085.
https://doi.org/10.1016/j.jtho.2024.03.008

has been cited by the following article:

• TITLE: Immunotherapy for Small Cell Lung Cancer

  AUTHORS: Yuxuan Ge, Xi Tang

  KEYWORDS: Small Cell Lung Cancer, Immunotherapy, PD-L1 Inhibitor, PD-1 Inhibitor

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.8, August 27, 2024

  ABSTRACT: Small cell lung cancer (SCLC) is a poorly differentiated, highly malignant neuroendocrine tumor characterized by rapid growth, aggressiveness, and easy recurrence. It is usually found in late clinical stage and the opportunity for surgery is lost. Therefore, surgery is often not used in clinical treatment. Although it is sensitive to chemoradiotherapy, it has a high recurrence rate and lacks effective treatment methods at present. Following chemotherapy and radiotherapy, immunotherapy for small cell lung cancer has become the mainstream research direction. Immunotherapy is profoundly changing the approach to cancer treatment due to its tolerable safety profile, sustained treatment response due to the production of immune memory, and effectiveness in a broad patient population. Immunotherapy for small cell lung cancer is one of the effective treatment methods for small cell lung cancer, and relevant studies are not rare, but there are still shortcomings such as intolerance of side effects and inaccurate evaluation of treatment timing. This article reviews the history of immunotherapy, the mechanism of action of immunodrugs, and the current immunodrugs used in the first-line treatment of extensive small cell lung cancer.